As part of Blood Cancer Awareness Month, we will be providing short updates on each clinical trial which is being facilitated by the Trials Acceleration Programme (TAP) Network that the charity currently funds.

Name of Clinical Trial:

Aims of the trial:
-Monitor how well Zanubrutinib works for Primary Central Nervous System (PCNSL),
– Discover what happens to Zanubrutinib in the body,
– To study how Zanubrutinib affects the body,
– Monitor side effects

Open in 14 Hospitals across the country

PRiZM+ is a phase 2 study of a novel inhibitor therapy called Zanubrutinib when treating patients with a rare and aggressive B cell lymphoma involving the primary central nervous system (PCNSL) – usually the brain. This is a particularly devastating condition because it causes neurological impairment (it is a brain tumour and a blood cancer). The most common form of PCNSL is diffuse large B cell lymphoma (DLBCL).

Zanubrutinib targets a particular enzyme that DLBCL needs to grow and divide. By doing so, it stops the DLBCL from growing.

Patients treated in PRiZM+ have had at least one line of previous treatment (often high dose, intensive chemotherapy) and their disease (PCNS) has returned.

Relapsed PCNSL is usually associated with a short survival – measured in months – so this is a huge area of unmet need.

Importantly, the protocol allows recruitment of patients who do not have the capacity to provide informed consent (due to effects of their disease), through a legal representative – this is important as such patients are typically excluded from accessing novel therapies through clinical trials.

The trial is designed as a platform study which means we plan to introduce other novel treatments into the trial to allow combinations of drugs to further improve response an remission rates.

The trial has been open for nearly a year and is due to close on 31st October 2023, and is recruiting very well for a rare disease.

PRiZM+ is classified as a platform trial, so the recruitment is staged in cohorts. Centres are currently recruiting to Cohort 1 which currently involves 15 patients. The current cohort will finish recruitment by December 2023 with active plans to extend recruitment to 2024 and beyond.